A Digital Tongue Diagnosis Model for High- and Low-risk Esophagogastroduodenal Varices in Cirrhosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-01

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this observational study is to establish an AI deep learning model that can dianosie high-risk varices for patients with cirrhosis effeciently.

The main question of this study is to esplore:

question 1: Developing a digital tongue diagnosis model, specifically a deep learning model to diagnose high-risk esophageal and gastric varices (HRV) associated with cirrhosis using sublingual vein images. Answering the question of whether the new tongue diagnosis method can accurately diagnose.

Question 2: Compare the diagnostic efficacy digital tongue diagnosis model with diagnostic models constructed using other biochemical indicators for HRV in cirrhosis, and answer the question of "how to use it optimally."

Question 3: Exploring the correlation between sublingual vein characteristics and Hepatic venous pressure gradient (HVPG).

Question 4: Compared with endoscopic examination results, validate the diagnostic performance of the model (AUC ≥ 0.90) and screen for key parameters of sublingual vein characteristics (such as sublingual vein varicosity diameter, vein length, color, etc.).

Question 5: Follow-up tongue examination images of patients with cirrhosis who underwent treatment (e.g., endoscopy, splenic embolization, TIPS, etc.) at 1, 2, and 3 years post-treatment were evaluated to assess the efficacy of digital tongue examination models in predicting high-risk esophageal and gastric variceal bleeding at 1, 2, and 3 years post-treatment, as well as the efficacy in predicting endoscopic treatment failure rates and patient mortality associated with bleeding.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study

NCT02593799

Liver Cirrhosis Esophageal and Gastric Varices

COMPLETED

Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis

NCT04210297

Esophageal and Gastric Varices

COMPLETED

Liver and Spleen Stiffness Measured by TE and 2D-SWE for Diagnosis of GOV in Patients With cACLD

NCT06144437

Liver Cirrhosis Liver Fibrosis Portal Hypertension

UNKNOWN

Radiomics-based Surrogate of Endoscopy (rEndosc) (CHESS1703)

NCT03373123

Esophageal Varices in Cirrhosis of the Liver

WITHDRAWN NA

Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)

NCT03990753

Compensated Cirrhosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Firstly, participants will be divided into two groups according to their degree of esophageal varices from endoscopic examination and CT report, including high-risk varices (HRV) group and low-risk varices (LRV) group. Secondly, participants will be asked to show their tongue, including the surface and sublingual veins of tongue, and the tongue images of each participants will be collected by researchers via camera. After finishing tongue image collection, participants will receive a professional tongue diagnosis report in Traditional Chinese Medicine and health suggestion. Finally, tongue images will be analyzed by AI deep learning model and some specifialized information will be estracted exactly. Besides, 60 patietns will be selected to eplore whtether sublingual vein characteristics is assoicated with HVPG. Finally, patietns will be followed up during 3 years, and gastric variceal bleeding, endoscopic treatment failure rates, and patient mortality risks related to bleeding will be analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Varices Liver Cirrhosis Sublingual Varices Portal Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with high-risk of esophageal varices in liver cirrhosis

The maximum diameter of varices ≥ 5 mm or maximum diameter of varices \<5mm with positive red sign in patients with liver cirrhosis

tongue diagnosis

Intervention Type DIAGNOSTIC_TEST

The tongue image of participants will be collected via camera, and tongue images will be used for AI deep model learning analysis.

patients with low-risk of esophageal varices in liver cirrhosis

the maximum diameter of esophageal varices \< 5 mm without positive red sign in patients with liver cirrhosis.

tongue diagnosis

Intervention Type DIAGNOSTIC_TEST

The tongue image of participants will be collected via camera, and tongue images will be used for AI deep model learning analysis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tongue diagnosis

The tongue image of participants will be collected via camera, and tongue images will be used for AI deep model learning analysis.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-75 years (including both age limits), no gender restrictions;
2. Diagnosed with cirrhosis based on clinical presentation, laboratory tests, imaging studies, and/or histopathological examination;
3. Undergone upper gastrointestinal endoscopy within the past 3 months prior to enrollment and have complete endoscopic imaging records;
4. Undergone enhanced CT or MRI scan of the upper abdomen within the past month prior to enrollment;
5. Patients who consent to enrollment and have signed an informed consent form.

Exclusion Criteria

1. Patients who have previously undergone endoscopic treatment for esophageal or gastric varices, transjugular intrahepatic portosystemic shunt (TIPS), splenectomy, hepatectomy, balloon occlusion of the portal vein, or liver transplantation;
2. Patients with grade 2-3 ascites or overt hepatic encephalopathy;
3. Patients with a history of portal venous system thrombosis (including the portal vein, splenic vein, superior mesenteric vein, etc.) or portal venous cavernous transformation, and who have been diagnosed with thrombosis within the past two weeks;
4. Patients diagnosed with or suspected of having primary liver cancer or other advanced malignant tumors;
5. Patients with chronic obstructive pulmonary disease and right heart failure;
6. Male and female patients with moderate anemia (hemoglobin \<70 g/L);
7. Patients with poorly controlled diabetes or microvascular complications;
8. Patients with poorly controlled hypertension;
9. Patients with hematological disorders such as polycythemia vera;
10. Patients with local oral lesions affecting sublingual venous blood flow, such as Ludwig's angina, Lemierre syndrome, or complications following certain oral surgeries (e.g., scar contracture or hematoma after tongue or floor of mouth surgery);
11. Patients with sublingual venous varicosities;
12. Patients who have experienced other severe systemic infections within the past 2 weeks prior to enrollment;
13. Pregnant women and peripartum women;
14. Patients with mental disorders;
15. Patients with incomplete medical records;
16. Patients unable to cooperate in completing the clinical study;
17. Other reasons deemed unsuitable for participation by the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No